Cat. No.: HY-123772

CDK5 inhibitor 20-223

(Synonyms: CP668863)

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC₅₀s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent.

For research use only. We do not sell to patients.

Purity: 99.62%
CAS No.: 865317-30-2
Formula: C₁₉H₁₉N₃O
Molecular Weight:305.37

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

CDK5 inhibitor 20-223 Chemical Structure

CAS No.: 865317-30-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC₅₀s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent^[1].

IC₅₀ & Target^[1]

CDK2

6.0 nM (IC₅₀)

CDK5

8.8 nM (IC₅₀)

All CDK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
ASPC1	IC₅₀	1163 nM Compound: 21	Antiproliferative activity against human AsPC1 cells after 72 hrs by prestoblue assay Antiproliferative activity against human AsPC1 cells after 72 hrs by prestoblue assay	[PMID: 30343954]
BXPC-3	IC₅₀	>2000 nM Compound: 21	Antiproliferative activity against human BxPC3 cells after 72 hrs by prestoblue assay Antiproliferative activity against human BxPC3 cells after 72 hrs by prestoblue assay	[PMID: 30343954]
MIA PaCa-2	IC₅₀	861 nM Compound: 21	Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by prestoblue assay Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by prestoblue assay	[PMID: 30343954]

In Vitro

CDK5 inhibitor 20-223 (10 nM-10 μM; 72 hours) potently inhibits cell growth in a panel of colorectal cancer (CRC) cell lines^[1].
CDK5 inhibitor 20-223 (0.3125-20 μM; 6 hours) induces a dose-dependent decrease in pRB (S807/811) and pFAK (S732) levels in each of the three CRC cell lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

CRC cell lines SW620, DLD1, HT29, HCT116, FET, CBS, and GEO cells
Concentration:

10 μM, 1 μM, 100 nM, 10 nM
Incubation Time:

72 hours
Result:

Reduced cell growth. IC50s of 168±20, 480±41, 360±72, 763±92, 117±49, 568±49, 79±31 nM for SW620, DLD1, HT29, HCT116, FET, CBS, and GEO cells.

Western Blot Analysis^[1]

Cell Line:

CRC cell lines GEO, HCT116 and HT29
Concentration:

20, 10, 5, 2.5, 1.25, 0.625, 0.3125 μM
Incubation Time:

6 hours
Result:

Did not affect the total levels of CDK2/5, and the levels of total FAK or total Retinoblastoma protein (Rb).
Induced a dose-dependent decrease in pRB (S807/811) and pFAK (S732) levels.

In Vivo

CDK5 inhibitor 20-223 (8mg/kg; subcutaneously; for 14 injections) shows anti-tumor activity in human CRC xenograft tumors in nude mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Athymic nude mice^[1]
Dosage:

8 mg/kg
Administration:

Injections were given subcutaneously daily for the first week and every other day for two more weeks for a total of 14 injections.
Result:

Reduced tumor growth and tumor weight in vivo.

Chemical Information

CAS No. 865317-30-2
Appearance Solid
Molecular Weight 305.37
Formula C₁₉H₁₉N₃O
Color Light yellow to yellow
SMILES

O=C(NC1=NNC(C2CCC2)=C1)CC3=CC=C4C=CC=CC4=C3
Synonyms

CP668863
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All

Sort by:

Journal Impact Factor

Cell

The immunoproteasome disturbs neuronal metabolism and drives neurodegeneration in multiple sclerosis. [Abstract]

2025 Aug 21;188(17):4567-4585.e32. PMID: 40532699

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (327.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2747 mL

16.3736 mL

32.7472 mL

5 mM

0.6549 mL

3.2747 mL

6.5494 mL

10 mM

0.3275 mL

1.6374 mL

3.2747 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (16.37 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Caroline M Robb, et al. Characterization of CDK(5) Inhibitor, 20-223 (Aka CP668863) for Colorectal Cancer Therapy. Oncotarget. 2017 Dec 28;9(4):5216-5232. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2747 mL	16.3736 mL	32.7472 mL	81.8679 mL
	5 mM	0.6549 mL	3.2747 mL	6.5494 mL	16.3736 mL
	10 mM	0.3275 mL	1.6374 mL	3.2747 mL	8.1868 mL
	15 mM	0.2183 mL	1.0916 mL	2.1831 mL	5.4579 mL
	20 mM	0.1637 mL	0.8187 mL	1.6374 mL	4.0934 mL
	25 mM	0.1310 mL	0.6549 mL	1.3099 mL	3.2747 mL
	30 mM	0.1092 mL	0.5458 mL	1.0916 mL	2.7289 mL
	40 mM	0.0819 mL	0.4093 mL	0.8187 mL	2.0467 mL
	50 mM	0.0655 mL	0.3275 mL	0.6549 mL	1.6374 mL
	60 mM	0.0546 mL	0.2729 mL	0.5458 mL	1.3645 mL
	80 mM	0.0409 mL	0.2047 mL	0.4093 mL	1.0233 mL
	100 mM	0.0327 mL	0.1637 mL	0.3275 mL	0.8187 mL

Keywords

CDK5 inhibitor 20-223

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

CDK5 inhibitor 20-223

Bioactive Compound Library Max

Bioactive Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Targeted Diversity Library

Anti-Colorectal Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) CDK5 inhibitor 20-223

All CDK Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

CDK5 inhibitor 20-223

Bioactive Compound Library Max

Bioactive Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Targeted Diversity Library

Anti-Colorectal Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) CDK5 inhibitor 20-223

All CDK Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

CDK5 inhibitor 20-223 Related Classifications

HY-123772 Related Classifications